Apremilast
- Generic Name
- Apremilast
- Brand Names
- Otezla, Apremilast Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24N2O7S
- CAS Number
- 608141-41-9
- Unique Ingredient Identifier
- UP7QBP99PN
- Background
Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as Roflumilast and Crisaborole. Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation.
- Indication
Apremilast is indicated for the treatment of adults with active psoriatic arthritis and adults with oral ulcers associated with Behcet's Disease. In addition, apremilast is indicated for the treatment of plaque psoriasis, of any severity, in adult patients who are candidates for phototherapy or systemic therapy.
- Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis), Active Psoriatic arthritis, Ulceration of the mouth
An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
- Conditions
- Chronic Prostatitis With Chronic Pelvic Pain SyndromeProstatitis
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Kenneth Peters, MD
- Target Recruit Count
- 21
- Registration Number
- NCT00701311
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis
- First Posted Date
- 2008-02-04
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 260
- Registration Number
- NCT00606450
- Locations
- 🇨🇦
Innovaderm, Montreal, Quebec, Canada
🇨🇦Dr Yves Poulin, Quebec City, Quebec, Canada
🇨🇿Department of Dermatovererology, Praha, Czechia
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 19
- Registration Number
- NCT00604682
- Locations
- 🇺🇸
University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States
🇺🇸NYU School of Medicine, New York, New York, United States
🇺🇸Mt Sinai School of Medicine, New York, New York, United States
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
- Conditions
- Psoriasis-Type PsoriasisPlaque-Type Psoriasis
- Interventions
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT00521339
- Locations
- 🇺🇸
Oregon Medical Research Center, P.C., Portland, Oregon, United States
🇺🇸Central Dermatology, Saint Louis, Missouri, United States
🇺🇸Tufts-New England Medical Center Hospitals, Boston, Massachusetts, United States
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2020-06-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 204
- Registration Number
- NCT00456092
- Locations
- 🇬🇧
Chapel Allerton Hospital, Leeds, United Kingdom
🇬🇧Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
🇨🇦Credit Valley Rheumatology, Mississauga, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.